SCHEMBL1110342

SCHEMBL1110342

CCCCC(C(=O)O)N(c1ccc2cc(-c3nc(C(=O)OCC)no3)ccc2c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.34
MMP9 P14780 6/20 0.34
MMP12 P39900 6/20 0.34
MMP13 P45452 5/20 0.34
MMP8 P22894 4/20 0.34
BMP1 P13497 1/20 0.33
ALDH1A1 P00352 2/20 0.32
P2RX3 P56373 1/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
HSD17B10 Q99714 2/20 0.31
POLB P06746 2/20 0.31
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
PPARG P37231 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110146 0.89 MMP2 (0.36) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110214 0.87 MMP2 (0.32) MMP2BMP1P2RX3TP53POLB
SCHEMBL1110145 0.86 KDM4E (0.41) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110250 0.84 MMP12 (0.38) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110163 0.84 PPARG (0.41) MAPTPPARGPPARDPPARAL3MBTL1
SCHEMBL1110220 0.83 NPC1 (0.42) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL1110299 0.83 KEAP1 (0.39) KMT2ASMN1; SMN2MAPTPPARG
SCHEMBL1110207 0.83 ALDH1A1 (0.45) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1321251 0.83 MMP12 (0.36) MMP2MMP9MMP12MMP13MMP8
SCHEMBL1110337 0.83 FFAR1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 MMP2 3127/4885MMP9 3948/4885MMP12 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.